Research & Development
Pipeline
Our investigational medicine programs reflect Novarix's commitment to science-led innovation across critical therapeutic areas.
Clinical Development Pipeline
Cardiovascular
NXL-201
Advanced Heart Failure
A novel cardiac myosin activator designed to improve cardiac output in patients with reduced ejection fraction heart failure — without increasing myocardial oxygen demand.
87% Complete
Endocrinology
NXL-312
Type 2 Diabetes
A dual GIP/GLP-1 receptor agonist demonstrating superior glycaemic control with significant weight reduction in large-scale Phase III clinical trials across 14 countries.
95% Complete
Oncology
NXL-405
Metastatic Breast Cancer
An antibody-drug conjugate (ADC) targeting HER2-low breast cancer. Phase II interim results show a 38% objective response rate in heavily pre-treated patient populations.
58% Complete
Neurology
NXL-109
Early Alzheimer's Disease
A first-in-class tau aggregation inhibitor targeting early Alzheimer's pathological cascade. Phase I safety data demonstrates a clean tolerability profile across all dose cohorts.
30% Complete
Immunology
NXL-518
Rheumatoid Arthritis
A selective JAK1 inhibitor with a differentiated safety profile under pre-clinical evaluation. Early data shows strong anti-inflammatory activity with minimal off-target effects.
Pre-clinical
Respiratory
NXL-223
Severe Asthma
A novel biologic targeting the IL-33/ST2 axis for severe eosinophilic asthma. Phase I dose-escalation study initiated across 6 clinical sites with promising safety signals.
25% Complete
Note: Pipeline information is subject to change based on ongoing clinical research and regulatory review.
Our Innovation Engine
Genetic Insights
Advanced genomics and proteomics identify novel drug targets and enable personalized treatment strategies for complex diseases.
AI-Driven Discovery
Machine learning and deep neural networks accelerate drug screening, predict molecular interactions, and optimize lead compounds at scale.
Clinical Excellence
Partnering with leading global medical institutions to conduct rigorous, patient-centric trials that meet international regulatory standards.
Our Research Leaders
Leading experts driving innovation and discovery across Novarix's therapeutic programs.
Dr. Meera Sundaram
Chief Scientific Officer
20+ years in clinical pharmacology and translational medicine research across multiple therapeutic areas.
Dr. Jonathan Aris
Head of Drug Discovery
Pioneering computational chemistry and AI-driven target validation for novel small molecule therapeutics.
Dr. Sophie Vane
VP Clinical Development
Expert in Phase II/III trial design and regulatory strategy with proven track record of FDA approvals.
Dr. Marcus Thorne
Senior Research Scientist
Specialist in cardiovascular and metabolic disease pathways with 15+ published research papers.
Interested in Partnership?
We collaborate with research institutions, biotech firms, and healthcare organisations globally to advance our pipeline.
Get in Touch